Immunohemolytic Anemia

Slide 1 · Immunohemolytic Anemia

Antibody-mediated red-cell destruction

Warm antibody

IgG • 37°C

Cold agglutinin

IgM • low temperature

Cold hemolysin

IgG • biphasic

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain immune mechanisms of premature erythrocyte destruction.

Interpret direct and indirect antiglobulin tests.

Distinguish warm, cold agglutinin, and cold hemolysin patterns.

Link pathogenesis to morphology, symptoms, and management principles.

Slide 3 · Defining immunohemolytic anemia

Antibodies recognize erythrocytes and shorten their survival.

Red-cell injury can be mediated through phagocytes or complement.

An ingested medication may initiate the immune reaction.

Antigen-bearing red cell

Antibody binding determines the immune mechanism

Schematic

Slide 4 · Why the terminology matters

Immunohemolytic

Includes antibodies induced by a drug

Emphasizes immune mechanism rather than origin

Autoimmune hemolytic

Often used for the same clinical group

Strictly implies an immune response to self antigens

Slide 5 · The hemolytic-anemia context

Premature erythrocyte destruction shortens red-cell survival below the normal 120 days.

Erythropoietin rises and marrow erythropoiesis compensates.

Products of hemoglobin degradation accumulate.

Anemia and hemolysis

Bilirubin → jaundice

Macrophage activity

Schematic

Slide 6 · Where red cells are destroyed

Extravascular

Sequestration and phagocytosis in spleen, liver, or marrow

Often accompanies reduced red-cell deformability

Intravascular

Red cells rupture within the circulation

Complement activation can be responsible

Slide 7 · A shared response to premature hemolysis

Red-cell survival decreases

Tissue oxygenation falls

Renal erythropoietin rises

Marrow erythropoiesis expands

The peripheral blood shows reticulocytosis when compensation is effective.

Slide 8 · Extravascular hemolysis: Signature consequences

Splenic sequestration accompanies reduced red-cell deformability.

Persistent phagocytosis can produce splenomegaly.

Anemia, jaundice, and splenic enlargement are major clinical features.

Spleen

Reduced deformability → sequestration

Schematic

Slide 9 · Intravascular hemolysis: Signature consequences

Free plasma hemoglobin can exhaust haptoglobin binding.

Hemoglobinemia and red-brown hemoglobinuria may follow.

Renal hemosiderosis and iron loss can occur with persistent hemolysis.

Intravascular RBC lysis

Free Hb → hemoglobinuria

Schematic

Slide 10 · Morphologic response to chronic hemolysis

Increased marrow erythroid precursors reflect compensatory erythropoiesis.

Reticulocytes increase in peripheral blood.

Hemosiderin can accumulate in macrophage-rich organs.

Prolonged hemolysis may cause pigment gallstones.

Anemia and hemolysis

Bilirubin → jaundice

Macrophage activity

Schematic

Slide 11 · Three immunohemolytic patterns

Type

Dominant antibody

Characteristic setting

Warm antibody

IgG (occasionally IgA); active at 37°C

Primary, autoimmune disease, neoplasm, drug

Cold agglutinin

IgM; avid binding at 0–4°C

Infection or chronic B-cell disorder

Cold hemolysin

IgG; binds in cooler tissues

Typically postviral children

Slide 12 · Mechanistic classification

Antibody binds the red cell

Fc receptor or complement engagement

Extravascular removal or in-circulation lysis

The antibody class, thermal behavior, and effector pathway explain the distinct phenotypes.

Slide 13 · Diagnostic principle: Demonstrate immune coating

Testing seeks immunoglobulin and/or complement on patient erythrocytes.

The direct antiglobulin (Coombs) test identifies such surface coating.

The indirect test examines antibody reactivity in patient serum.

Ig / C3

Anti-human

Ig / C3

Agglutination indicates coating of patient RBCs

Schematic

Slide 14 · Direct antiglobulin test: Analytic steps

Obtain patient erythrocytes

Add anti-human Ig / complement reagent

Observe whether erythrocytes agglutinate

Visible clumping supports the presence of surface-bound human Ig or complement.

Slide 15 · What a positive direct Coombs test means

Antiglobulin reagent bridges erythrocytes coated with human Ig or complement.

The reaction demonstrates coating, not the degree of red-cell destruction.

Interpret the reaction together with evidence of hemolysis.

Ig / C3

Anti-human

Ig / C3

Agglutination indicates coating of patient RBCs

Schematic

Slide 16 · Indirect antiglobulin test: Analytic steps

Patient serum is obtained

React serum with antigen-defined test red cells

Observe antigen-dependent reactivity

This method helps characterize target specificity and temperature dependence.

Slide 17 · Direct versus indirect antiglobulin testing

Direct test

Analyte: Coating on patient red cells

Uses anti-human Ig/complement to reveal in-vivo binding

Direct evidence for immune red-cell sensitization

Indirect test

Analyte: Antibodies in patient serum

Uses test cells with defined antigens

Helps define target specificity and temperature behavior

Slide 18 · Start with the phenotype, not the test alone

Identify evidence of shortened red-cell survival and compensatory erythropoiesis.

Determine whether destruction is predominantly extravascular or intravascular.

Use immune testing to define the antibody-mediated component.

Antibody-coated RBC

Fc-mediated

Phagocytosis

Complement

Injury

Schematic

Slide 19 · Warm antibody type: Relative frequency

Approximately 80% of immunohemolytic anemias are warm-antibody type.

Antibodies bind stably to erythrocytes at 37°C.

Most are IgG; IgA accounts for less common cases.

IgG

IgG

IgG

Antibody-coated erythrocyte

Recognition precedes premature destruction

Schematic

Slide 20 · Warm antibodies at core body temperature

Binding remains stable at physiologic body temperature.

Circulating coated red cells encounter Fc-receptor-bearing phagocytes.

This favors extravascular rather than direct intravascular destruction.

IgG-coated cell

Fc-receptor phagocyte

Extravascular clearance

Schematic

Slide 21 · Warm autoantibody antigen targets

In primary disease, the initiating cause is not known.

Antibodies often recognize red-cell surface proteins.

Proteins associated with the Rh blood-group complex are frequent targets.

Antigen-bearing red cell

Antibody binding determines the immune mechanism

Schematic

Slide 22 · Warm hemolysis: Fc-mediated clearance

IgG coats erythrocytes

Macrophage Fc receptors engage bound IgG

Partial phagocytosis removes membrane

Spherocytes enter the splenic clearance pathway

The antibody marks the cell for recognition; Membrane loss transforms its mechanics.

Slide 23 · Partial phagocytosis is not complete lysis

Macrophages remove portions of the erythrocyte membrane.

Loss of surface area without equivalent volume loss produces spherocytes.

These cells have less capacity to deform through splenic channels.

Biconcave red cell

Spherocyte

Membrane lost; Deformability reduced

Schematic

Slide 24 · Why spherocytes are destroyed in the spleen

Erythrocyte membrane area falls

Spheroid shape reduces deformability

Splenic passage becomes difficult

Sequestration permits phagocytosis

The same shape-to-sequestration principle appears in hereditary spherocytosis.

Slide 25 · Spherocytes: Finding and differential

In warm immunohemolysis, spherocytes reflect acquired membrane loss.

An inherited membrane defect can also produce spherocytes.

The immune mechanism is distinguished by appropriate antiglobulin evidence.

Biconcave red cell

Spherocyte

Membrane lost; Deformability reduced

Schematic

Slide 26 · Why the spleen becomes enlarged

Continued erythrocyte removal increases splenic phagocytic activity.

Macrophage hyperplasia underlies the usual moderate splenomegaly.

The organ is both a site of injury and a clinical marker of chronicity.

Spleen

Reduced deformability → sequestration

Schematic

Slide 27 · Warm antibody anemia: Etiologic categories

Primary

Approximately 50% of warm cases are idiopathic

Cause of loss of immune tolerance remains unknown

Secondary

Autoimmune disorders, especially systemic lupus erythematosus

Lymphoid neoplasms or drug exposure

Slide 28 · Warm immune hemolysis and systemic autoimmunity

Systemic lupus erythematosus is an important associated disorder.

The hemolytic process remains antibody-mediated.

Recognizing a systemic setting changes the etiologic classification.

IgG

IgG

IgG

Antibody-coated erythrocyte

Recognition precedes premature destruction

Schematic

Slide 29 · Warm immune hemolysis and lymphoid neoplasms

Lymphoid neoplasms can underlie a secondary warm-antibody process.

The red-cell injury is immune-mediated, not necessarily direct neoplastic infiltration.

Seek the associated condition when disease is not idiopathic.

IgG-coated cell

Fc-receptor phagocyte

Extravascular clearance

Schematic

Slide 30 · Medication-triggered immune hemolysis

Some drugs initiate an antibody response that injures red cells.

Two mechanisms are emphasized: New antigenic determinants and loss of tolerance.

Distinguishing them clarifies the antibody target.

Drug

New antigenic determinant on red cell

Schematic

Slide 31 · Antigenic-drug mechanism

Drug attaches to erythrocyte membrane

A new antigenic determinant forms

Antibodies recognize drug-associated cell

Opsonization or complement injury follows

Penicillin and cephalosporins are examples.

Slide 32 · Antigenic-drug timing and exposure

Typically follows large intravenous doses of the offending drug.

Onset around 1–2 weeks after therapy begins.

Drug bound to the red-cell membrane is recognized by antibody.

Drug

New antigenic determinant on red cell

Schematic

Slide 33 · Drug-associated red-cell destruction routes

Extravascular route

Antibodies function as opsonins

Phagocytes remove coated erythrocytes

More common in the described antigenic-drug mechanism

Intravascular route

Antibody may fix complement

Complement-mediated injury lyses red cells within the circulation

Reported but less common in this mechanism

Slide 34 · Tolerance-breaking drug mechanism

A medication disrupts immune tolerance

Autoantibodies against native erythrocyte antigens appear

Rh-complex targets are common

Clinical hemolysis may develop

The exact process through which tolerance is disrupted is unknown.

Slide 35 · α-Methyldopa: The prototype

The classic tolerance-breaking example is α-methyldopa.

About 10% of exposed individuals develop detectable red-cell autoantibodies.

Roughly 1% develop clinically significant hemolysis.

Drug exposure

Immune tolerance disrupted

Autoantibody to native RBC antigen

Schematic

Slide 36 · Antibody positivity is not equivalent to anemia

A positive direct antiglobulin test indicates surface-bound immune material.

The α-methyldopa example shows that immune sensitization may be clinically silent.

Evidence of active red-cell destruction is still needed for interpretation.

Ig / C3

Anti-human

Ig / C3

Agglutination indicates coating of patient RBCs

Schematic

Slide 37 · Drug-related immune mechanisms compared

Feature

Antigenic-drug mechanism

Tolerance-breaking mechanism

Initial event

Drug binds RBC and creates determinant

Drug disrupts tolerance

Target of antibody

Drug-associated membrane complex

Native RBC antigens (often Rh)

Classic examples

Penicillin; cephalosporins

α-Methyldopa

Dominant injury

Opsonization; sometimes complement

Autoantibody-mediated RBC removal

Slide 38 · Principles of warm-antibody management

Identify and remove initiating factors such as causative drugs when possible.

When this cannot be achieved, immunosuppressive medication is a mainstay.

Splenectomy targets a key site of red-cell sequestration and destruction.

Spleen

Reduced deformability → sequestration

Schematic

Slide 39 · Cold agglutinin type: The defining antibody

IgM antibodies bind red cells strongly at low temperatures, especially 0–4°C.

They do not bind stably at 37°C.

This category accounts for approximately 15–20% of immunohemolytic anemia.

IgM-mediated red-cell agglutination

Schematic

Slide 40 · Cold agglutinins: Acute and chronic settings

Acute / transient

May follow an infection

Most such antibodies produce little clinically significant hemolysis

Chronic

May be idiopathic

May be associated with certain B-cell neoplasms

Slide 41 · Infectious associations of cold agglutinins

Mycoplasma pneumoniae is a classic association.

Epstein–Barr virus and cytomegalovirus are reported triggers.

Influenza virus and HIV are additional associations.

Cool periphery

Binding

Warm core

Recirculation

The site and temperature of binding determine the outcome

Schematic

Slide 42 · Why many infection-related cases resolve

Cold agglutinins may arise only transiently during an infection.

The textbook characterizes these episodes as self-limited.

Clinically important hemolysis is uncommon in such episodes.

IgM-mediated red-cell agglutination

Schematic

Slide 43 · Chronic cold agglutinin disease: Context

An idiopathic form is described.

Certain B-cell neoplasms are associated with chronic disease.

These cases can be more difficult to treat than transient episodes.

IgG

IgG

IgG

Antibody-coated erythrocyte

Recognition precedes premature destruction

Schematic

Slide 44 · Cold exposure creates permissive vascular sites

Exposed fingers, toes, and ears can cool substantially.

IgM can bind erythrocytes where vascular temperatures fall below about 30°C.

Peripheral cold exposure therefore creates a localized risk of red-cell agglutination.

Cool periphery

Binding

Warm core

Recirculation

The site and temperature of binding determine the outcome

Schematic

Slide 45 · Cold agglutinin mechanism: First phase

Peripheral blood cools

IgM attaches to erythrocytes

Red cells agglutinate

Complement fixation begins

IgM binding is rapid in cool vascular beds.

Slide 46 · Cold-dependent red-cell agglutination

Multivalent IgM promotes visible erythrocyte clumping.

Agglutination is a physical vascular event, not by itself the entire hemolytic process.

The location of clumping helps explain acrocyanotic symptoms.

IgM-mediated red-cell agglutination

Schematic

Slide 47 · Cold agglutinin mechanism: Warming phase

IgM binds in cooler blood

Complement is fixed

Blood returns to warm central circulation

IgM dissociates; C3b remains

Transient coating can still be sufficient for opsonization.

Slide 48 · C3b explains delayed erythrocyte clearance

Sublytic C3b deposits remain on the erythrocyte membrane.

C3b is an efficient opsonin for macrophage recognition.

Subsequent destruction occurs mainly outside blood vessels.

C3b

C3b

C3b

Complement components deposited

C3b acts as an opsonin

Schematic

Slide 49 · Sites of extravascular cold-antibody hemolysis

C3b-opsonized red cells can be removed by phagocytes.

The spleen, liver, and bone marrow participate.

Hemolytic severity varies across affected patients.

IgG-coated cell

Fc-receptor phagocyte

Extravascular clearance

Schematic

Slide 50 · Why intravascular lysis is usually absent

IgM commonly dissociates as circulating blood warms.

It often departs before the complement cascade causes complete lysis.

C3b-mediated extravascular clearance is therefore typical.

C3b

C3b

C3b

Complement components deposited

C3b acts as an opsonin

Schematic

Slide 51 · Cold-related microvascular obstruction

Agglutinated erythrocytes can impair peripheral vascular flow.

Pallor and cyanosis may occur in cold-exposed sites.

Raynaud phenomenon is another recognized consequence.

IgM-mediated red-cell agglutination

Schematic

Slide 52 · Cold symptoms are mechanistically distinct

Vascular symptoms arise from aggregation in peripheral vessels.

Anemia arises from accelerated clearance of sensitized erythrocytes.

A patient may exhibit both effects of the same IgM response.

Cool periphery

Binding

Warm core

Recirculation

The site and temperature of binding determine the outcome

Schematic

Slide 53 · Principle of managing chronic cold agglutinin anemia

Avoidance of low environmental temperatures when feasible.

This reduces conditions favorable to peripheral IgM binding.

Associated conditions may complicate the clinical course.

Cool periphery

Binding

Warm core

Recirculation

The site and temperature of binding determine the outcome

Schematic

Slide 54 · Warm and cold agglutinin types: Mechanistic contrasts

Variable

Warm antibody type

Cold agglutinin type

Principal antibody

IgG; occasionally IgA

IgM

Thermal behavior

Stable binding at 37°C

Binding strongest in cold

Main opsonin

IgG / Fc engagement

C3b after transient IgM

Hemolytic compartment

Predominantly splenic

Spleen, liver, marrow

Clinical emphasis

Spherocytes and splenomegaly

Cold-related acrovascular symptoms

Slide 55 · Cold hemolysin type: A separate entity

This form causes paroxysmal cold hemoglobinuria.

The responsible antibody is IgG, not IgM.

It is a rare but potentially severe intravascular hemolytic disorder.

P antigen

IgG binds on cooling; Complement lysis follows warming

Schematic

Slide 56 · Paroxysmal cold hemoglobinuria: Antigen target

Cold hemolysin IgG recognizes the P blood-group antigen.

Binding occurs in cooler peripheral tissue vascular beds.

The red-cell target differs from that of typical warm antibodies.

P antigen

IgG binds on cooling; Complement lysis follows warming

Schematic

Slide 57 · Biphasic hemolysis in paroxysmal cold hemoglobinuria

IgG binds P antigen in the cold

Antibody sensitizes erythrocytes to complement

Blood recirculates to the warm core

Complement-mediated intravascular lysis

Binding and lysis are favored at different temperatures.

Slide 58 · Why the hemoglobinuria can be dramatic

Complement injury causes red cells to rupture in the circulation.

Released hemoglobin can appear in plasma and urine.

Hemolysis can be substantial and occasionally fatal.

Intravascular RBC lysis

Free Hb → hemoglobinuria

Schematic

Slide 59 · The characteristic pediatric context

Most described cases occur in children following viral infections.

The disorder is usually transient in that setting.

Most affected children recover within about one month.

Cool periphery

Binding

Warm core

Recirculation

The site and temperature of binding determine the outcome

Schematic

Slide 60 · Cold agglutinins versus cold hemolysins

Feature

Cold agglutinin

Cold hemolysin

Antibody class

IgM

IgG

Early cold event

Cell agglutination + C3b

Binding to P antigen

On warming

IgM often dissociates

Complement-mediated lysis

Dominant outcome

Extravascular removal

Intravascular hemolysis

Typical association

Infection or B-cell neoplasm

Postviral childhood episode

Slide 61 · Case exercise: Warm antibody pattern

Illustrative clinical scenario

An adult has anemia, splenic enlargement, spherocytes, and antibodies detected on their erythrocytes.

Interpretive question

Which immune effector explains the spherocytes?

Mechanistic interpretation

IgG-coated cells engage macrophage Fc receptors; Partial phagocytosis removes membrane, reducing deformability and favoring splenic clearance.

Slide 62 · Case exercise: Cold agglutinin pattern

Illustrative clinical scenario

An adult develops pallor and cyanosis of exposed fingers in cold weather; Erythrocytes agglutinate in cooled blood.

Interpretive question

Why can the same process cause anemia?

Mechanistic interpretation

Cold-bound IgM fixes complement. Residual C3b promotes later macrophage clearance after IgM dissociates in warmer blood.

Slide 63 · Case exercise: Biphasic cold hemolysis

Illustrative clinical scenario

A child develops red-brown urine after a recent viral illness; An IgG antibody binds red cells in cold peripheral blood.

Interpretive question

Which mechanism explains intravascular hemolysis?

Mechanistic interpretation

Cold-reactive IgG binds P antigen; Complement activity after rewarming can lyse the red cells within the circulation.

Slide 64 · A mechanistic diagnostic sequence

Establish hemolysis

Demonstrate antibody/complement coating

Determine immunoglobulin class and thermal behavior

Recognize effector pattern and underlying context

This sequence links a laboratory finding to a pathophysiologic diagnosis.

Slide 65 · Three patterns: One immune principle

Warm

Binding at 37°C

IgG–Fc receptor axis

Partial phagocytosis → spherocytes

Cold agglutinin

Cold IgM binding

C3b opsonization

Extravascular clearance + vascular clumping

Cold hemolysin

Cold IgG binds P antigen

Lysis on rewarming

Intravascular hemoglobin release

Slide 66 · Integrated clinicopathologic synthesis

Spherocytes point toward membrane removal and splenic sequestration.

Cold-triggered acral symptoms point toward erythrocyte agglutination.

Hemoglobinuria in postviral childhood illness raises the cold-hemolysin pattern.

The direct antiglobulin test supplies immune evidence, not the whole diagnosis.

Antibody-coated RBC

Fc-mediated

Phagocytosis

Complement

Injury

Schematic

Slide 67 · Key learning points

Antibody thermal behavior determines where sensitization occurs.

The effector mechanism—not simply the presence of antibody—determines hemolysis.

Warm IgG favors splenic clearance; Cold IgM favors C3b opsonization.

Biphasic cold-reactive IgG can cause major intravascular hemolysis.

Antigen-bearing red cell

Antibody binding determines the immune mechanism

Schematic

Slide 68 · Primary reference and source limitations

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026).

Chapter 14: Red Blood Cell and Bleeding Disorders, pp. 579–580 and 590–591.

Text and table facts were adapted from the supplied Robbins Markdown; original chapter PDF images were not supplied or reproduced.